Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16) (q23;p13) chromosome translocation

Noriko Satake, Yasushi Ishida, Yoshiko Otoh, Shin Ichi Hinohara, Hirofumi Kobayashi, Akiko Sakashita, Nobuo Maseki, Yasuhiko Kaneko

Research output: Contribution to journalArticle

74 Scopus citations

Abstract

CBP, which is located on 16p13 and encodes a transcriptional adaptor/coactivator protein, has been shown to fuse by the t(8;16)(p11;p13) translocation to MOZ on 8p11 in acute myeloid leukemia. We found a t(11;16)(q23;p13) in a child with therapy-related chronic myelomonocytic leukemia. Subsequent reverse transcriptase-polymerase chain reaction and direct sequencing analyses revealed the MLL-CBP fusion transcript in CMML cells. Because 11q23 translocations involving MLL and t(8;16) involving MOZ and CBP have been reported in therapy-related leukemias, both the MLL and CBP genes may be targets for topoisomerase II inhibitors. Accordingly, we believe that most t(11;16)-associated leukemias may develop in patients who have been treated with cytotoxic chemotherapy for primary malignant diseases.

Original languageEnglish (US)
Pages (from-to)60-63
Number of pages4
JournalGenes Chromosomes and Cancer
Volume20
Issue number1
DOIs
StatePublished - Sep 1997
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Fingerprint Dive into the research topics of 'Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16) (q23;p13) chromosome translocation'. Together they form a unique fingerprint.

  • Cite this